We investigated the anti-angiogenic effects of the water extract of HangAmDan (WEHAD), which is a crude extract of nine Korean medicinal substances of animal and plant origin. In human umbilical vein endothelial cells, WEHAD significantly inhibited bFGF-induced proliferation, adhesion, migration, and capillary tube formation. We used an antibody array to perform an analysis of signaling proteins, which showed up-regulated expression of various proteins including RAD51, RAD52, and p73, and down-regulated expression of pFAK. Blood vessel formation in a chick chorioallantoic membrane (CAM) treated with WEHAD was markedly reduced in length compared with a PBS-treated control group. These results suggest that inhibition of angiogenesis by WEHAD may be the mechanism of action for the anti-cancer effects of HAD.
Angiogenesis, which is the formation of new blood vessels from existing endothelium, is an essential process in various physiological and pathological situations including wound repair, organ regeneration, embryonic vascular system development and tumorigenesis. Tumor growth and metastasis are highly dependent on angiogenesis [1, 2] . Treatments for human cancer that inhibit angiogenesis are the subject of intensive clinical investigation and, therefore, better understanding of the fundamental mechanisms of angiogenesis is critical in developing and improving these novel therapeutic options.
Angiogenesis is a complex process that involves the proliferation and migration of endothelial cells. It is delicately controlled by a variety of inducers and inhibitors that respectively cause the up-and down-regulation of angiogenesis [3, 4] . It has been reported that most actively-studied basic fibroblast growth factors (bFGFs) and vascular endothelial growth factors (VEGFs) work as angiogenic inducers for both in vivo and in vitro growth [5] [6] [7] . Many kinds of angiogenic inhibitors have already been discovered including angiostatin, which decreases bFGF-and VEGF-mediated activation of MAPK in endothelial cells leading to inhibition of proliferation and induction of apoptosis [8] . Furthermore, Soamsan, a traditional Korean medicinal extract of herbal materials, has been shown to have anti-angiogenic effects and has been used to treat cardiovascular diseases [9] . Therapeutic inhibitors have been found using ProteoChip-based library screening methods. For instance, the A5-1 peptide that is effective as an angiogenesis inhibitor against integrin α5β1 [10] , and certain Korean medicinal plant extracts chosen under the same methodology have been verified to possess anti-angiogenic functions [11] , have been identified using this methodology.
HangAmDan (HAD) is composed of nine products from species of Korean medicinal plants and animals (Table 1) , and has been used for the treatment of cancer patients in oriental medicine. We have investigated how the water extract of HAD (WEHAD) inhibits bFGF-induced angiogenesis using assays to measure the proliferation, migration, and adhesion of human umbilical vein endothelial cells (HUVECs) in vitro, and an ex vivo chorioallantoic membrane (CAM) angiogenesis assay.
Materials and methods

Preparation of water extract of HAD
HAD was provided by the East-West Cancer Center of the Dunsan Oriental Medical Hospital of Daejeon University (Daejeon, Korea) ( Table 1 ). The WEHAD was prepared by extracting HAD powder with 1 g of powder in 10 mL of distilled water at room temperature for 24 h. The extract was centrifuged at 1000×g for 30 min and then filtered and lyophilized. The extract powder was dissolved directly in distilled water.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were provided from Innopharmascreen Inc. (Asan, Korea). Cells were cultured in a complete M199 medium (Invitrogen, CA, USA). The cells at passages 3-6 were used. HUVEC cultures were kept maintained routinely at 37°C in a humidified atmosphere of 5% CO 2 , and used for assay at passages 3-6. 
In vitro HUVEC adhesion assay
An adhesion substrate was prepared by adding 100 μL of vitronectin (10 μg mL −1 ; Sigma, St. Louis, USA) diluted in phosphate-buffered saline (PBS; pH 7.3) to 96-well ELISA plates (Nunc) overnight at 4°C. Each well was then washed twice with PBS to remove unbound vitronectin and blocked for 30 min at 37°C with 0.1% bovine serum albumin (BSA) in PBS. After blocking, the wells were washed three times with PBS. HUVECs (5×10 5 cells mL −1 ) were added to each well of a 96-well plate coated with fibronectin. HUVEC suspension (100 μL) including either fresh media (negative control) or WEHAD (30-1000 μg mL
) and bFGF (5 ng mL
) was added to three wells and incubated for 90 min at 37°C. After incubation, unbound cells were removed by rinsing each well twice with PBS and incubated for 1 h at 37°C with 100 μL 1% Coomassie blue solution (v/v) that diluted with MeOH. The optical density (A) at 595 nm of each well was measured using a spectrophotometer (Emax, Molecular Devices, USA). The presented data were measured in triplicate.
In vitro HUVEC migration assay
A migration assay was performed as previously [13, 14] . HUVECs were placed in a modified Boyden chamber (48-well chemotaxis chamber AP48; Neuro Probe, Gaithersburg, MD, USA). Polycarbonate membranes (8 μm pore, 25 mm×80 mm in size, polyvinylpyrrolidine-free; Neuro Probe) were coated with gelatin and incubated overnight at 37°C. Basic FGF (5 ng mL −1 ) in M199 was added to the lower chamber, and cell suspension containing 1×10 4 cells per 50 μL media and supplemented with the indicated concentration of medicinal extracts was added to the upper chamber of each well. The chamber was incubated for 8 h at 37°C with 5% CO 2 to allow cells to migrate through the gelatin-coated polycarbonate membrane. Non-migrating cells on the upper surface of the membrane were removed with a wiper tool (Neuro Probe), and the membrane was then stained with Diff-Quik (VWR Scientific Products, Bridgeport, NJ, USA). The total number per well of migrating cells with nuclei was determined as described. The evaluated data showed the relative cell migration, which is a percentage compared with the mean cell number for each stained field. The presented data were measured in triplicate.
In vitro capillary tube formation
Capillary tube formation of HUVECs was performed as described with some modification [15] . Twenty four-well culture plates were coated with 250 μL of Matrigel and allowed to solidify at 37°C for 30 min. HUVECs (2×10 5 cells) were added to each of three wells in 100 μL of media containing WEHAD and bFGF of 5 ng mL −1 (or fresh media as a negative control). After 18 h of incubation, the capillary tubes were fixed, stained with a Diff-Quick solution (Becton Dickinson, San Jose, CA, USA) and observed under a phase-contrast microscope.
Ex vivo bFGF-induced CAM angiogenesis
An ex vivo CAM assay was performed as previously described [16, 17] . Fertilized eggs were incubated at 37°C in humidified air. Ovalbumin (4-5 mL) was extracted from the bottom of the eggs using a syringe on day 3, and windows were made within the tops of the eggs. The windows were sealed with transparent tape, and the eggs were further incubated until day 9. Thermonox (Nunc, Naperville, IL) containing bFGF (200 ng) or bFGF plus extract was implanted onto the CAM of an individual embryo. After a 48 h incubation period, intralipose (a white fat emulsion solution) was injected into the CAM for clear visualization of blood vessel formation, and each CAM was observed under a microscope and photographed.
Protein expression profiling in WEHAD-treated HUVEC
Preparation of cell lysates
When HUVECs reached confluence, they were serumstarved by incubation in M199 containing 1% FBS for 8 h.
The cells were treated with or without WEHAD in the presence of growth factor. After 24 h incubation, the cells were washed twice with PBS and harvested in 5 mmol L −1
EDTA-PBS. The harvested cells were then maintained on ice for 10 min and centrifuged for 5 min at 1300 r min −1 .
The pellets were washed with PBS and re-centrifuged.
Protein extraction and labeling
HUVECs were extracted with Lysis-M ™ (Roche, Germany) mammalian cell extraction buffer. Each protein extract (100 μg, 1 mg mL −1 ) was labeled with both Cy3 and Cy5 (GE Healthcare, UK) as per the manufacturer's instructions. Free dyes were removed with SigmaSpin columns (S5059, Sigma, USA) and purified samples were stored at 4°C until use.
Preparation of antibody microarrays
Forty-eight distinct antibodies against proteins involved in cell proliferation (Hypromatrix, Worcester, MA, USA) were spotted onto ProteoChip arrays in duplicate. The detailed procedure of array analysis has been previously described [18] .
Hybridization
The fluorescence-labeled cell lysates were applied onto the antibody array and incubated for 1 h at 37°C in the dark. The slides were washed three times with PBST, N 2 -dried and analyzed using a fluorescence microarray scanner.
Detection and data analysis
The antibody array slides were scanned using a GenePix 4100A microarray scanner (Axon Instruments, Union City, CA, USA) with 532 and 635 nm lasers. Image analysis was performed for each spot using the manufacturer's software package (GenePix 6.0, Axon Instruments). The INR (internally normalized ratio) of all spots were calculated as previously described [19] .
Western-blot analysis
The cell pellets were lysed using Complete Lysis M (Roche). Protease and phosphatase inhibitor cocktails (both from Roche) were added. Protein extracts (50 μg) were separated on a 12% Bis-Tris Nupage gel (Invitrogen) and transferred onto a PVDF membrane. The membrane was blocked with 5% non-fat milk, or BSA in PBS (pH 7.4) containing 0.5% Tween-20. It was then incubated with rabbit anti-FAK (1 : 1000 dilution), rabbit anti-Rad51 (1 : 1000 dilution), rabbit anti-p73 (1 : 1000 dilution), or rabbit anti-GAPDH (1 : 500 dilution) for 16 h at 4°C. The membrane was subsequently incubated with horseradish peroxidase-conjugated anti-rabbit secondary antibodies for 60 min at room temperature. Protein bands were visualized on a medical X-ray film (Agfa) using an enhanced chemiluminescence (ECL ™ ) kit (Invitrogen).
Results and discussion
Biological characterization of WEHAD effects on bFGF-induced HUVECs
To investigate the biological activities of WEHAD, we performed proliferation, migration, and adhesion assays using HUVECs. As an antagonistic extract, WEHAD markedly inhibited the proliferation of HUVECs compared with the PBS-treated control group ( Figure 1A) . A half-maximal inhibition of proliferation on the endothelial cells by WEHAD was observed at a concentration of 253 μg mL −1 .
To confirm the anti-angiogenic functions of WEHAD, an in vitro HUVEC adhesion assay and a migration assay were employed. WEHAD suppressed bFGF-induced cell attachment in a dose-dependent manner ( Figure 1B) . The antiadhesive efficacy of WEHAD was higher than that of RGD.
WEHAD also prevented bFGF-induced cell migration in a dose-dependent manner compared with the PBS control group ( Figure 1C) . To further assess the inhibitory effects of the antagonistic extracts on HUVEC proliferation, we carried out an in vitro capillary tube formation assay, and ex vivo CAM angiogenesis. Cells plated on Matrigel were treated for 16 h with WEHAD in the presence of bFGF and tube formation was observed using phase-contrast microscopy. WEHAD significantly suppressed tube formation at a concentration of 10 μg mL −1 (Figure 2A ). The area of CAM below the disks without any treatment showed a normal density and branching pattern of the blood vessels, indicating that disk weight did not affect their growth. By contrast, the vascular branches of CAM treated with WEHAD (10 μg/ egg) for 48 h were perturbed ( Figure 2B ). These findings are consistent with data obtained from HUVEC proliferation, adhesion, migration, and tubular network formation assays. Collectively, these results suggest that WEHAD could be useful for the development of a potent angiogenesis inhibitor.
Expression profiling of cell cycle proteins in WEHAD-treated HUVECs using antibody microarray
The goal of this study was to analyze the expression pattern of endogenous signaling proteins in HUVECs treated with WEHAD. To investigate the protein expression profile in WEHAD-treated HUVECs, an antibody microarray constructed on ProteoChip was used. To carry out the antibody microarray analysis, WEHAD-treated HUVECs were labeled with Cy3 and Cy5. Antibody microarray analysis of WEHAD-treated HUVECs labeled with Cy5 compared with the Cy3-labeled untreated HUVECs revealed up-or down-regulation of different proteins ( Figure 3A and B) . A further attempt was made to validate the antibody microarray data by immunoblot analysis. Selected up-regulated proteins such as RAD51, Cyclin B1, and p73 showed increased expression, whereas down-regulated proteins such as FAK showed a decrease in protein amount in Western blotting analyses ( Figure 3C ).
Focal adhesion kinase (FAK) is a widely expressed cytoplasmic protein tyrosine kinase involved in integrin-mediated signal transduction. It plays an important role in the control of several biological processes including cell spreading, migration, and survival [20] . Our antibody array data indicate that the inhibitory effect of WEHAD on the proliferation of HUVECs may be partly due to the decreased expression of FAK involved in integrin-mediated cell survival. p73, a member of the p53 family, is involved in cell cycle regulation, and induction of apoptosis. The p73-induced apoptosis is mediated by endoplasmic reticulum stress and induction of p53 up-regulated modulator of apoptosis (PUMA) [21, 22] . Our finding suggests that the inhibition of HUVEC proliferation by WEHAD may be mediated by induction of apoptosis in the cells via increased p73 expression. It was reported that enhancement of p53 ubiquitination by the FAK FERM domain promotes cell proliferation and cell survival [23] . Based on our antibody array data, WEHAD treatment of HUVECs caused down-regulation of FAK as well as up-regulation of p73, resulting in suppression of cell proliferation. Additionally, the DNA repair protein, RAD51, was regulated by WEHAD in HUVECs. Collectively, these data suggest that WEHAD significantly inhibits bFGF-induced angiogenesis through the regulation of expression of certain proteins involved in cell growth.
In this study, we observed anti-angiogenic effects of WEHAD in HUVECs through different angiogenesis assays induced by bFGF. WEHAD had dose-dependent inhibitory effects on proliferation, migration and adhesion (Figure 1) . We also verified this inhibitory effect through an ex vivo CAM assay ( Figure 2B ). Thus, WEHAD may have a potential therapeutic utility in the treatment of cancers involving neovascularization. However, as we already described, WEHAD is a natural product made up of nine types of plants and animals, i.e., it contains many types of compounds. Thus, further attempts will be made to examine the molecular mechanism correlated with cellular signaling pathways, and to identify the active compounds that appear to create the anti-angiogenic effects of WEHAD. 
